XWXu Wang

Xu Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xu Wang has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Huabing Zhang

    Department of Biochemistry and Molecular Biology, Metabolic Disease Research Center, School of Basic Medicine, Anhui Medical University, Hefei, China

    2 shared publications
  • Aizhen Xiong

    The MOE Key Laboratory of Standardization of Chinese Medicines, Shanghai Key Laboratory of Compound Chinese Medicines, SATCM Key Laboratory of New Resources and Quality Evaluation of Chinese Medicines, and State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

    1 shared publication
  • Anqiang Zhang

    Wound Trauma Medical Center, State Key Laboratory of Trauma and Chemical Poisoning, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing 400042, China

    1 shared publication
  • Chiea Chuen Khor

    Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore

    1 shared publication
  • Ching-Yu Cheng

    National University of Singapore

    1 shared publication
  • Da Teng

    Department of General Surgery, The First Medical Centre, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Hepatocyte CBX2 Safeguards Hepatic Lipid Homeostasis by Elevating Ca 2+ ‐CaMKK2‐AMPK Signaling to Counter MASLD

    by Xiang Wei, Li Lin, Xiuyun Wang, Hui Du, Menglong Zhang, Kechao Tang, Han Gao, Xinrui Xie, Jingya Gao, Xu Wang, et al.

    Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects approximately one‐third of adults and lacks effective pharmacological therapies. Here, we identify Chromobox 2 (CBX2), a Polycomb‐associated chromatin regulator, as a previously unrecognized regulator of hepatic lipid homeostasis. CBX2 expression is markedly reduced in hepatocytes from patients with MASLD, multiple mouse models ( db/db , ob/ob , HFD, and HFHC), and steatotic hepatocytes in vitro . Hepatocyte‐specific CBX2 overexpression ameliorates hepatic steatosis, improves glucose metabolism, and suppresses inflammation, whereas CBX2 deficiency exacerbates these metabolic disturbances. Mechanistically, CBX2 enhances H3K4me3 enrichment at the Orai1 promoter, promoting Orai1 transcription and increasing intracellular Ca 2+ levels. Elevated Ca 2+ activates the CaMKK2‐AMPK signaling pathway, leading to ACC phosphorylation, inhibition of de novo lipogenesis (FAS, ACC, and SCD‐1), enhancement of fatty acid oxidation (PPARα and CPT‐1a), and suppression of NF‐κB/JNK‐mediated inflammation. Genetic and pharmacological interventions further establish the necessity of this Ca 2+ ‐CaMKK2‐AMPK axis for CBX2‐mediated metabolic protection. Collectively, our findings reveal a CBX2‐driven metabolic regulatory circuit and highlight CBX2 and its downstream signaling pathway as potential therapeutic targets for MASLD.

  • Shengmai San formula alleviates high-fat diet-induced obesity in mice through gut microbiota-derived bile acid promotion of M2 macrophage polarization and thermogenesis

    by Zixuan Wang, Xu Wang, Lihong Fu, Shuyang Xu, Xunjiang Wang, Qi Liao, Tongxi Zhuang, Longchan Liu, Haoyue Zhang, Wei Li, et al.


  • Open Access

    Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma

    by Rui Sun, Xu Wang, Jiajie Chen, Da Teng, Shixin Chan, Xucan Tu, Zhenglin Wang, Xiaomin Zuo, Xiang Wei, Li Lin, et al.

    Background: Cellular senescence is a typical irreversible form of life stagnation, and recent studies have suggested that long non-coding ribonucleic acids (lncRNA) regulate the occurrence and development of various tumors. In the present study, we attempted to construct a novel signature for predicting the survival of patients with hepatocellular carcinoma (HCC) and the associated immune landscape based on senescence-related (sr) lncRNAs.Method: Expression profiles of srlncRNAs in 424 patients with HCC were retrieved from The Cancer Genome Atlas database. Lasso and Cox regression analyses were performed to identify differentially expressed lncRNAs related to senescence. The prediction efficiency of the signature was checked using a receiver operating characteristic (ROC) curve, Kaplan–Meier analysis, Cox regression analyses, nomogram, and calibration. The risk groups of the gene set enrichment analysis, immune analysis, and prediction of the half-maximal inhibitory concentration (IC50) were also analyzed. Quantitative real-time polymerase chain reaction (qPCR) was used to confirm the levels of AC026412.3, AL451069.3, and AL031985.3 in normal hepatic and HCC cell lines.Results: We identified 3 srlncRNAs (AC026412.3, AL451069.3, and AL031985.3) and constructed a new risk model. The results of the ROC curve and Kaplan–Meier analysis suggested that it was concordant with the prediction. Furthermore, a nomogram model was constructed to accurately predict patient prognosis. The risk score also correlated with immune cell infiltration status, immune checkpoint expression, and chemosensitivity. The results of qPCR revealed that AC026412.3 and AL451069.3 were significantly upregulated in hepatoma cell lines.Conclusion: The novel srlncRNA (AC026412.3, AL451069.3, and AL031985.3) signatures may provide insights into new therapies and prognosis predictions for patients with HCC.


  • Open Access

    Association of NAD + ADP-ribosyltransferase 1 gene polymorphism with the development of neonatal diabetes mellitus

    by Xin Fu, He Nan, Zhen Liu, Lirong Zhang, Xu Wang

    Regulation of glucose metabolism by NAD-dependent ADP-ribosyltransferase is well investigated in different populations. Genetic variations NAD+ ADP-ribosyltransferase has been shown to alter the activity of the enzyme and associated with susceptibility to diabetes. However, reports on neonatal diabetes are minimal. We, therefore, in the present report aimed to investigate the involvement of NAD+ ADP-ribosyltransferase variants as a possible risk factor for predisposition to neonatal diabetes mellitus in Chinese patients. Neonatal subjects diagnosed with diabetes mellitus and healthy infants from a similar geographical area were enrolled at China-Japan Union Hospital of Jilin University, China. The involvement of NAD+ ADP-ribosyltransferase with neonatal diabetes mellitus was investigated in DNA samples of all participants by PCR methods. One hundred Twenty neonatal diabetes mellitus cases and a matched number of healthy neonates were enrolled in the present study. GG and G SNPs of NAD+ ADP-ribosyltransferase were mainly involved in developing neonatal diabetes mellitus and the individuals with GA SNPs protect responsible for protecting from neonatal diabetes mellitus. Thus, NAD+ ADP-ribosyltransferase involved in neonatal diabetes mellitus and risk of developing is approx. 2 times higher compared to healthy subjects. Our finding showed that polymorphism in NAD+ ADP-ribosyltransferase gene is associated with the predisposition to neonatal diabetes mellitus in Chinese. The present study also suggested that NAD+ ADP-ribosyltransferase is a promising target for the treatment of neonatal diabetes mellitus and an effective care of patients. Our study results encourage conducting further investigation in the multi-centric clinical genetic study including larger samples to assesses the role of NAD+ ADP-ribosyltransferase polymorphism in neonatal diabetes mellitus.

  • Open Access

    The potential roles of long non‐coding RNAs in lipopolysaccharide‐induced human peripheral blood mononuclear cells as determined by microarray analysis

    by Anqiang Zhang, Hongxiang Lu, Dalin Wen, Jianhui Sun, Juan Du, Xu Wang, Wei Gu, Jianxin Jiang

    Sepsis arises from an aberrant and excessive host response to infection. Long noncoding RNAs (lncRNAs) are involved in multiple cellular functions, including inflammation and immunity. However, to date there has been no systematic attempt to identify lncRNAs whose expression is changed after the induction of the innate immune response. In this study, we profiled global lncRNA and mRNA expression changes in peripheral blood mononuclear cells (PBMCs) treated with lipopolysaccharide (LPS) using a microarray platform. Of the 40 914 lncRNAs screened, 596 were significantly upregulated and 250 were significantly downregulated (corrected P < 0.05) in response to LPS. Of the 34 236 mRNAs screened, 802 were upregulated and 549 were downregulated. Functional annotation analysis indicated that lncRNA‐associated differentially expressed mRNAs were primarily enriched in host immune and inflammatory responses. This study provides the first lncRNA and mRNA transcriptomic landscape of LPS‐mediated changes in human PBMCs. These findings may provide potential insights into lncRNAs involved in the immunopathology of sepsis.


  • Open Access

    Evaluation of transethnic fine mapping with population-specific and cosmopolitan imputation reference panels in diverse Asian populations

    by Xu Wang, Ching-Yu Cheng, Jiemin Liao, Xueling Sim, Jianjun Liu, Kee-Seng Chia, E-Shyong Tai, Peter Little, Chiea-Chuen Khor, Tin Aung, et al.

    There has been limited success in identifying causal variants underlying association signals observed in genome-wide association studies (GWAS). The use of 1000 Genomes Project (1KGP) allows the imputation to estimate the genetic information at untyped variants. However, long stretches of high linkage disequilibrium within the genome prevent us from differentiating between causal variants and perfect surrogates, thus limiting our ability to identify causal variants. Transethnic strategies have been proposed as a possible solution to mitigate this. However, these studies generally rely on imputing genotypes from multiple ancestries from 1KGP but not against population-specific reference panels. Here, we perform the first transethnic fine-mapping study across three Asian cohorts from diverse ancestries at the loci implicated with eye and blood lipid traits, using population-specific reference panels that have been generated by whole-genome sequencing samples from the same ancestry groups. Our study outlines several challenges faced in a fine-mapping exercise where one simply aims to meta-analyse existing GWAS that have been imputed against reference haplotypes from the 1KGP.